hrp0082p2-d1-415 | Growth Hormone | ESPE2014

IGF1 is Associated with a More Favourable Pattern of Body Composition in Obese Children

Inzaghi Elena , Pampanini Valentina , Alessio Paola , Fiori Rossana , Ferroli Barbara Baldini , Cianfarani Stefano

Background: Recent studies have suggested a role of IGF1 as a candidate prognostic marker for cardiometabolic complications of obesity.Objective: To investigate the relationship between IGF1 serum levels and both biochemical and metabolic parameters as well as body composition in a cohort of obese children.Methods: obese subjects (130F/157M), aged 11.2±2.7 years, were studied. Anthropometry, biochemical and metabolic parameter...

hrp0084p1-108 | Perinatal | ESPE2015

Liver ER Stress and Intrauterine Growth Retardation in Rats

Deodati Annalisa , Argemi Josepmaria , Puglianiello Antonella , Germani Daniela , Ferrero Roberto , Aragon Tomas , Cianfarani Stefano

Background: Endoplasmic reticulum (ER) is the site where proteins are folded. Perturbation of ER homeostasis activates a set of ER-to-nucleus signaling reactions known as the unfolded protein response (UPR). Metabolic stress causes UPR activation which contributes to the development of insulin resistance and metabolic syndrome. As UPR can be activated by nutrient and oxygen starvation, we postulated that intrauterine growth restriction may trigger UPR signaling and thereby con...

hrp0084p3-581 | Adrenals | ESPE2015

New Mutation Causing Systemic Pseudohypoaldosteronism

Pedicelli Stefania , Cambiaso Paola , Zennaro Maria-Christina , Ferro Giusy , Cianfarani Stefano , Cappa Marco

Background: Pseudohypoaldosteronism (PHA) is a rare heterogeneous syndrome of mineralocorticoid resistance. PHA type 1 (PHA1) is characterized by neonatal salt loss, failure to thrive, dehydration and circulatory shock. It includes two forms: renal (autosomal dominant), due to mutations in mineralocorticoid receptor coding gene NR3C2, and systemic (autosomal recessive), due to mutations in subunit genes of the epithelial sodium channel (ENaC). ENaC is constituted of three subu...

hrp0084p3-712 | Diabetes | ESPE2015

A Novel Compound Heterozygous Mutation in an Adolescent with Insulin-dependent Diabetes: A Case Report of Wolfram Syndrome

Maltoni Giulio , Mantovani Vilma , Zucchini Stefano , Cristalli Carlotta Pia , Minardi Raffaella , Mazzanti Laura

Background: Wolfram syndrome (WS) is an autosomal recessive neurodegenerative disorder characterized by non-autoimmune diabetes mellitus and progressive optic atrophy. WS includes other possible disorders, such as diabetes insipidus, sensorineural deafness, genitourinary tract problems, neurological or psychiatric disorders and others.Case presentation: A 12-years-old boy presented with glicosuria and shortly developed insulin-dependent diabetes mellitus...

hrp0094p2-477 | Thyroid | ESPE2021

L-T4 absorption test in 14-year-old patient with severe refractory hypothyroidism after total thyroidectomy

Vincenzi Gaia , Di Stefano Marina , Abbate Marco , Tarantola Giulia , Barera Graziano , Vigone Maria Cristina

Hypothyroid patients post-thyroidectomy require 1.6-1.8 mg/kg/die of Levothyroxine (L-T4). A persistent TSH level above the upper limit despite a daily dose >1.9 mg/kg/die is defined as “refractory” hypothyroidism in adults. Malabsorption and “pseudo-malabsorption” need to be investigated in case of therapeutic failure. L-T4 absorption test (LT4AT) is useful in distinguishing these two conditions but it has only been described in adult age. We ...

hrp0097p1-136 | Multisystem Endocrine Disorders | ESPE2023

Endocrinopathies in Congenital Disorder of Glycosylation (CDG): Short stature and hypergonadotropic hypogonadism are the main endocrinological manifestations in two unrelated cases of PMM2-CDG.

Del Medico Giulia , Procopio Elena , Ferri Lorenzo , Annibalini Giosuè , Morrone Amelia , Stagi Stefano , Barbieri Elena

Introduction: PMM2-CDG is the most common congenital disorder of glycosylation (CDG). Since glycoproteins are involved in every endocrine axis, PMM2-CDG patients have a high risk of developing endocrinopathies.Case report: We describe two 12 years-old female PMM2-CDG patients with severe short stature and no clinical sign of puberty. One patient showed low serum levels of insulin-like growth factor-1 (IGF-1) and IGF bind...

hrp0097p2-124 | Bone, Growth Plate and Mineral Metabolism | ESPE2023

Clinical case: a misleading family history

Pitea Marco , Lanzafame Ruggero , Sala Elisa , Crocè Ludovica , Mora Stefano , Sgaramella Paola , Weber Giovanna , Barera Graziano

A 17-year-old girl comes to our attention for a second opinion due to reduced bone mineralization. She has a family history of osteogenesis imperfecta: her mother and younger sister have a COL1A1 mutation. The girl never had any fractures, but considering the familiarity it was carried out a DEXA, showing a Z-score of -1.9 SDS at the femoral level and -2 SDS at the lumbar level; no fractures visible in the spine X-ray. The genetic analysis of COL1A1 was carried out, which came...

hrp0095p1-508 | Growth and Syndromes | ESPE2022

Real-world experience with Vosoritide for achondroplasia: interim findings from an early access programme in France

Cormier-Daire Valérie , Cohen Shelda , Edouard Thomas , Isidor Bertrand , Mukherjee Swati , Pimenta Jeanne , Rossi Massimiliano , Schaefer Elise , Sigaudy Sabine , Baujat Geneviève

Introduction: Achondroplasia is caused by a pathogenic mutation in the FGFR3 gene, leading to impaired endochondral bone growth and multiple medical complications. Vosoritide (once daily, subcutaneous injection) has recently been approved by the European Medicines Agency (EMA) for treating achondroplasia in patients aged ≥2 years until closure of epiphyses. It has been made available in France via an early access program, a cohort Temporary Authorization fo...

hrp0092rfc12.5 | Growth and Syndromes (to include Turner syndrome) | ESPE2019

Cognitive and Neuroradiological Assessments in Silver Russell Patients

Patti Giuseppa , De Mori Letizia , Tortora Domenico , Savina Severino Maria , Calevo Mariagrazia , Morana Giovanni , Rossi Andrea , Casalini Emilio , Napoli Flavia , Di Iorgi Natascia , Maghnie Mohamad

Silver-Russell syndrome (SRS) is an epigenetic disorder characterized by severe intrauterine and postnatal growth retardation and typical dysmorphic features. The most common genetic abnormalities are 11p15 ICR1 loss of methylation, (11p15 LOM) and maternal uniparental disomy of chromosome 7 (mUPD7). There is little information on cognitive development in SRS patients and no neuroradiological studies are available so far. Global developmental delay and requirement for speech t...

hrp0097rfc4.5 | Growth and syndromes (to include Turner syndrome) | ESPE2023

Real-world safety and effectiveness of vosoritide: Results from an early access program in France

Cormier-Daire Valérie , Edouard Thomas , Isidor Bertrand , Cohen Shelda , Mukherjee Swati , Pimenta Jeanne , Lhaneche Leila , Rossi Massimiliano , Schaefer Elise , Goodman Erin , Sigaudy Sabine , Baujat Geneviève

Introduction: Achondroplasia is the most common skeletal dysplasia, in which the main clinical feature is short stature. Vosoritide, the first specific treatment for achondroplasia; administered as a daily subcutaneous injection, was approved by the European Medicines Agency in August 2021 for patients aged ≥2 years until closure of epiphyses. French Health Authorities granted early access to vosoritide treatment in France on 24 June 2021, which continued u...